Dana DiRenzo, MD, MHS
Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, spoke with Healio about recently approved treatment options for rheumatoid arthritis, highlighting the role of JAK-inhibitors in RA management and factors that may increase an individual’s risk for RA. In this video, DiRenzo discusses:
- Recent FDA approvals of treatments for rheumatoid arthritis, including JAK-inhibitors such as upadacitinib (Rinvoq, AbbVie), tofacitinib (Xeljanz, Pfizer) and baricitinib (Olumiant, Eli Lilly);
- Her own clinical experience using new treatments in practice, noting that JAK-inhibitors most benefit patients with treatment refractory RA;
- Patients who would not benefit from treatment with interleukin 6 receptor inhibitors, and when drugs in this class are best used;
- Treatment recommendations for patients with early RA; and
- Important areas of research and clinical study that will impact the future of RA treatment and management.